Literature DB >> 21931353

Is GDNF beneficial in Parkinson disease?

Barry J Hoffer, Brandon K Harvey.   

Abstract

Entities:  

Year:  2011        PMID： 21931353      PMCID： PMC3830920          DOI： 10.1038/nrneurol.2011.149

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson's disease: a real-time PCR study.

Authors:  Cristina M Bäckman; Lufei Shan; Ya Jun Zhang; Barry J Hoffer; Sherry Leonard; Juan C Troncoso; Paul Vonsatel; Andreas C Tomac
Journal:  Mol Cell Endocrinol       Date:  2006-04-27       Impact factor: 4.102

2.  Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease.

Authors:  D G Walker; T G Beach; R Xu; J Lile; K D Beck; E G McGeer; P L McGeer
Journal:  Brain Res       Date:  1998-05-11       Impact factor: 3.252

3.  GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

Authors:  Mickael Decressac; Ayse Ulusoy; Bengt Mattsson; Biljana Georgievska; Marina Romero-Ramos; Deniz Kirik; Anders Björklund
Journal:  Brain       Date:  2011-06-28       Impact factor: 13.501

4.  Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease.

Authors:  Arianna Bellucci; Laura Navarria; Michela Zaltieri; Elisa Falarti; Serena Bodei; Sandra Sigala; Leontino Battistin; Mariagrazia Spillantini; Cristina Missale; Pierfranco Spano
Journal:  J Neurochem       Date:  2011-01-19       Impact factor: 5.372

5.  Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease.

Authors:  Steven S Gill; Nikunj K Patel; Gary R Hotton; Karen O'Sullivan; Renée McCarter; Martin Bunnage; David J Brooks; Clive N Svendsen; Peter Heywood
Journal:  Nat Med       Date:  2003-03-31       Impact factor: 53.440

6.  Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.

Authors:  J H Kordower; S Palfi; E Y Chen; S Y Ma; T Sendera; E J Cochran; E J Cochran; E J Mufson; R Penn; C G Goetz; C D Comella
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

7.  Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo.

Authors:  J Hudson; A C Granholm; G A Gerhardt; M A Henry; A Hoffman; P Biddle; N S Leela; L Mackerlova; J D Lile; F Collins
Journal:  Brain Res Bull       Date:  1995       Impact factor: 4.077

8.  Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.

Authors:  Jamie L Eberling; Adrian P Kells; Philip Pivirotto; Janine Beyer; John Bringas; Howard J Federoff; John Forsayeth; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

9.  Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease.

Authors:  Anthony E Lang; Steven Gill; Nik K Patel; Andres Lozano; John G Nutt; Richard Penn; David J Brooks; Gary Hotton; Elena Moro; Peter Heywood; Matthew A Brodsky; Kim Burchiel; Patrick Kelly; Arif Dalvi; Burton Scott; Mark Stacy; Dennis Turner; V G Frederich Wooten; William J Elias; Edward R Laws; Vijay Dhawan; A Jon Stoessl; James Matcham; Robert J Coffey; Michael Traub
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

10.  Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons.

Authors:  M Trupp; M Rydén; H Jörnvall; H Funakoshi; T Timmusk; E Arenas; C F Ibáñez
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539
  10 in total
  7 in total

1.  Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.

Authors:  Luis Quintino; Giuseppe Manfré; Erika Elgstrand Wettergren; Angrit Namislo; Christina Isaksson; Cecilia Lundberg
Journal:  Mol Ther       Date:  2013-07-24       Impact factor: 11.454

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

3.  Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase.

Authors:  Saurabh Khasnavis; Anamitra Ghosh; Avik Roy; Kalipada Pahan
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

4.  The proform of glia cell line-derived neurotrophic factor: a potentially biologically active protein.

Authors:  Xiao-Long Sun; Bei-Yu Chen; Li Duan; Yi Xia; Zhuo-Jing Luo; Jing-Jie Wang; Zhi-Ren Rao; Liang-Wei Chen
Journal:  Mol Neurobiol       Date:  2013-08-10       Impact factor: 5.590

5.  Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model.

Authors:  Anja Drinkut; Karsten Tillack; Durga P Meka; Jorg B Schulz; Sebastian Kügler; Edgar R Kramer
Journal:  Cell Death Dis       Date:  2016-09-08       Impact factor: 8.469

Review 6.  Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms.

Authors:  Liliane Tenenbaum; Marie Humbert-Claude
Journal:  Front Neuroanat       Date:  2017-04-10       Impact factor: 3.856

Review 7.  Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2.

Authors:  Simona M Wagner; ShuJun Zhu; Adrian C Nicolescu; Lois M Mulligan
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.